CONSOLIDATED STATEMENTS OF OPERATIONS (USD $) In Thousands, except Share data, unless otherwise specified	12 Months Ended
	Apr. 30, 2014	Apr. 30, 2013
Operating revenue:
Personalized oncology solutions	$ 2,264	$ 2,390
Translational oncology solutions	9,286	5,933
Total operating revenue	11,550	8,323
Costs and operating expenses:
Cost of personalized oncology solutions	2,731	2,672
Cost of translational oncology solutions	3,532	2,656
Research and development	2,265	1,920
Sales and marketing	3,155	2,665
General and administrative	6,127	4,631
Total costs and operating expenses	17,810	14,544
Loss from operations	(6,260)	(6,221)
Other expense:
Change in fair value of warrant liability	(965)	(74)
Other expense	(164)	(25)
Total other expense	(1,129)	(99)
Net loss before income tax expense	(7,389)	(6,320)
Provision for income tax	17	10
Net loss	$ (7,406)	$ (6,330)
Net loss per common share outstanding, including redeemable common stock, basic and diluted (in dollars per share)	$ (0.11)	$ (0.12)
Weighted average common shares outstanding, including redeemable common stock, basic and diluted (in shares)	66,863,915	52,046,766